Saving Lives with Therapies from Platelets

Cellphire Therapeutics, Inc. (“Cellphire”) is a clinical stage biotechnology company with a portfolio of novel, stabilized, allogeneic, platelet-derived, cellular therapeutics addressing markets in > $4 Billion.  Benefiting from significant historical and planned funding from the US Government, our therapeutics utilize proprietary process and formulation technologies.
Cellphire’s lead biologic CLPH-511 are frozen activated platelets for IV use with 5-year shelf life at –65⁰C. It is manufactured with scalable proprietary production by freezing pooled Group O leuko-reduced liquid stored platelets.  CLH-511 clinical trial was recently stopped due to efficacy at the Interim Analysis, having achieved Non-Inferiority, according to the Independent Data Monitoring Committee (DMC).  The randomized, parallel group, active comparator-controlled Phase 2/3 clinical trial [NCT04709705] to evaluate the non-inferiority or superiority of cryopreserved platelets with conventional platelets in controlling blood loss in patients under going cardiopulmonary bypass surgery.

Cellphire has two technologies in Phase 2 clinical trials, Freeze-dried Platelet-derived Hemostat (FPH), a stabilized platelet-derived biologic, and Cryopreserved Platelets (CPP).